Volume Alert - A 40.98 Agilent Technologies $A Hit a high

New Post Public Reply Private Reply Replies (0) Message Board
leahanne
Volume Alert - A 40.98 Agilent Technologies $A Hit a high today of 41.33 Closing the day 10:30 at 40.98 +0.18 +0.44% With a day low of 40.72 and a total volume of 1,182,998.

A Recent Posts: http://investorshangout.com/Agilent-Technologies-A-49958/

A Agilent Technologies Recent Headline News

Update: Agilent Earnings - Likely Upside On FY15 Guidance
AtonRa Partners - at Seeking Alpha - 2 hrs 42 mins ago

A: 40.98 (+0.18), TMO: 124.81 (+4.31), KEYS: 30.82 (-0.18), DHR: 82.56 (-0.02)

Agilent Beats on Q4 Earnings, Guides Above Expectations - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 19, 8:40AM CST
Agilent's (A) fiscal fourth-quarter 2014 earnings per share of 88 cents exceeded the Zacks Consensus Estimate by a good 38 cents.
RAX: 43.40 (+0.70), BIDU: 241.89 (-0.86), A: 40.98 (+0.18), AKAM: 61.86 (-0.30)

Global miRNA Market 2015-2019 - Increased Investment in miRNA-based Research and Drug Development
M2 - Wed Nov 19, 8:28AM CST
Research and Markets (http://www.researchandmarkets.com/research/lbw97q/global_mirna) has announced the addition of the "Global miRNA Market 2015-2019" report to their offering. The Global miRNA market to grow at a CAGR of 13.36% over the period 2014-2019 One of the main trends in this market is increased mergers and acquisitions. Many big pharmaceutical and biotechnology companies have acquired small life science and pharmaceutical companies to strengthen their business and expand their global presence. According to the report, one of the major drivers in this market is increased investment in miRNA-based research and drug development. The demand for advanced diagnostics tools is increasing rapidly. miRNAs have a great potential in diagnostics and treatment of several severe diseases, including cancer, and cardiovascular and neurological disorders. Further, the report states that one of the major challenges in this market is the delivery of miRNA-based drugs. Delivery of miRNA drugs into the desired cell or tissue in a body is a difficult procedure as any mistake in drug administration can lead to severe health defects. The Global miRNA market can be divided into different segments based on application: - miRNA Research - miRNA-based Diagnostics - Therapeutics Key Vendors - Affymetrix - Agilent Technologies - Exiqon - Qiagen - Thermo Fisher Scientific Key Topics Covered: - Executive Summary - List of Abbreviations - Scope of the Report - Market Research Methodology - Introduction - Market Landscape - Market Segmentation by Application - Geographical Segmentation - Buying Criteria - Market Growth Drivers - Drivers and their Impact - Market Challenges - Impact of Drivers and Challenges - Market Trends - Trends and their Impact - Vendor Landscape - Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/lb...obal_mirna
A: 40.98 (+0.18)

Agilent Technologies Falls 1.07% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Tue Nov 18, 4:17PM CST
Agilent Technologies (NYSE:A) traded in a range yesterday that spanned from a low of $40.05 to a high of $41.16. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $41.21 on volume of 5.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
A: 40.98 (+0.18)

After Yesterday's Decline of 1.07%, Agilent Technologies Offers Investors Better Value
Comtex SmarTrend(R) - Tue Nov 18, 4:16PM CST
Agilent Technologies (NYSE:A) traded in a range yesterday that spanned from a low of $40.05 to a high of $41.16. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $41.21 on volume of 5.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
A: 40.98 (+0.18)

Agilent Technologies (A) Earnings Report: Q4 2014 Conference Call Transcript
at The Street - Tue Nov 18, 11:36AM CST
The following Agilent Technologies (A) conference call took place on November 17, 2014, 05:30 PM ET. This is a transcript of that earnings call:
A: 40.98 (+0.18)

Agilent Technologies (A) Stock Sinks Today on Earnings Slip
at The Street - Tue Nov 18, 9:25AM CST
Agilent Technologies (A) stock is down after the company reported lower than expected fiscal fourth quarter earnings late yesterday.
A: 40.98 (+0.18)

Global miRNA Research and Diagnostics Markets Report 2014
M2 - Tue Nov 18, 9:13AM CST
Research and Markets (http://www.researchandmarkets.com/research/fjgcv3/mirna_research) has announced the addition of the "miRNA Research and Diagnostics Markets" report to their offering. This report considers the diagnostic promise of non-coding RNA molecules, with a particular focus on the microRNAs. miRNAs (MicroRNAs) are short, single stranded RNAs that regulate mRNA expression at the post-transcriptional level. These small bits of RNA, members of a class of non-translated molecules that donot produce protein, shut off gene transcription by base pairing with the target molecules. They are now recognized as pivotal regulators of gene expression; including development, proliferation, differentiation, and apoptosis and serving widespread functions as regulatory molecules in post-transcriptional gene silencing. As the report details, alarge number of companies, both small biotechs and big pharmaceutical companiesare committed to miRNA diagnostics. As part of its coverage of this topic, this report includes the following: - Overview of miRNAs - Positive Factors for miRNA Diagnostic Technologies - Negative Factors - miRNAs and Neurological Disorders - miRNA and Metastatic Brain Lesions - Prostate Cancer Screening and miRNAs - miRNAs and Resistance to Anti-Cancer Drugs - Theoretical Limitations - Discussion of Patent Issues - Interviews with Industry Experts - Market Estimate As part of its coverage, the miRNA offerings and products in developments in the following companies are profiled in detail: - Agilent Technologies - AMSBIO - Applied Biosystems - DiamiR, LLC - Dicerna - Eisai Biomarkers and Personalized Medicine - Diagnostics - Genomic Health Inc. - Gensignia - GlaxoSmithKline Discovery and Molecular Toxicology - Groove Biopharma (formerly Mirina) - Hologic-Gen Probe Inc. - Illumina, Inc. - Isis Pharmaceuticals - Mello Biotechnology Inc. - Microlin Bio - MiRagen Therapeutics - MiRNA Therapeutics - Novartis - Pacific Edge Biotechnology - Prolias Technologies - Regulus Therapeutics - Rosetta Genomics - Santaris Pharma A/S - Sirnaomics, Inc. - Somagenics - Diagnostics: Small RNA Assays and Biomarker Validation - Tekmira Pharmaceuticals Corporation - Thermadiag - Thermo Fisher Scientific, Inc. Key Topics Covered: 1. Executive Summary 2. Introduction 3. Current State of the Art 4. Companies Developing microRNA Diagnostic Technologies 5. Market Estimates and Forecasts 6. Interviews with Industry Experts: Biomarkers 7. The Future of miRNA-Based Diagnostics For more information visit http://www.researchandmarkets.com/research/fj...a_research
ISIS: 50.41 (+0.70), A: 40.98 (+0.18), TKMR: 16.36 (-0.01), ILMN: 190.17 (+0.32), RGLS: 16.66 (-1.46), GSK: 46.39 (+0.11), HOLX: 26.39 (-0.25), GHDX: 32.39 (-0.15), NVS: 95.82 (+0.24)

Agilent Revenues And Earnings Increase
Abba's Aces - at Seeking Alpha - Tue Nov 18, 8:35AM CST

A: 40.98 (+0.18)

Agilent's (A) CEO Bill Sullivan on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 18, 8:08AM CST

A: 40.98 (+0.18)

Downgrade Alert for Agilent Technologies (A)
Comtex SmarTrend(R) - Tue Nov 18, 7:57AM CST
Agilent Technologies (NYSE:A) was downgraded from Outperform to Market Perform at Cowen and Company today. The stock closed yesterday at $41.24 on volume of 2.7 million shares, below average daily volume of 2.8 million. Agilent Technologies, Inc. provides core bio-analytical and electronic measurement solutions to the communications, electronics, life sciences and chemical analysis industries. The Company's operations include electronic measurement, bio-analytical measurement, semiconductor and board testing.
A: 40.98 (+0.18)

Global Chiral Chromatography Column Market Outlook, 2018 - Key Analysis of the $87 Million Industry
M2 - Tue Nov 18, 5:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/vtffgd/chiral) has announced the addition of the "Chiral Chromatography Column Market by type, Material, & by Application - Forecast to 2018" report to their offering. The chiral chromatography columns market size was $68 million in 2013 and is expected to reach $87.8 million by 2018, at a CAGR of 5.2% Chiral Chromatography has evolved over the years and has become a method of choice for analysis, identification, and purification of a wide variety of compounds. The market has seen an extraordinary amount of technological advancements in the last few years, as companies have introduced new systems that perform chromatographic procedures in lesser amounts of time and provide more detailed results. This report categorizes the market into two broad segments, based upon type of columns, into empty columns and pre-packed columns. Thepre-packed columns market comprises of analytical and preparative columns. The analytical columns accounts for 62% of the overall market. The chiral chromatography columns market, by applications, is segmented into Liquid Chromatography (LC), Gas Chromatography (GC), Thin-layer chromatography (TLC),and Supercritical Fluid Chromatography (SFC). The LC market is further classified into High Performance Liquid Chromatography (HPLC), Ultra-High Performance Liquid Chromatography (UHPLC), Ultra-Fast Liquid Chromatography (UFLC) and Flash Chromatography. The Liquid chromatography (LC) subsegment holds the largest share 69% of the overall market in 2013. This high share of LC systems is attributed to the large-scale application of HPLC systems and the rising use of UHPLC systems. Key Topics Covered: 1 Introduction 2 Research Methodology 3 Executive Summary 4 Premium Insights 5 Market Overview 6 Chiral Chromatography Columns Market, By Type 7 Chiral Chromatography Market, By Material 8 Chiral Chromatography Market, By Application 9 Market, By End User 10 Geographic Analysis 11 Competitive Landscape 12 Company Profiles - Agilent Technologies - Daicel Corporation - Phenomenex, Inc. - Shimadzu Corporation - Sigma Aldrich Corporation - Thermo Fisher Scientific, Inc. - Waters Corporation For more information visit http://www.researchandmarkets.com/research/vtffgd/chiral
A: 40.98 (+0.18), WAT: 114.02 (-0.07)

Global Next Generation Sequencing (Genome/Exome Sequencing/DNA Sequencing) Market Forecasts and Opportunities, 2020 - Updated Report
M2 - Tue Nov 18, 4:25AM CST
Research and Markets (http://www.researchandmarkets.com/research/h58jql/next_generation) has announced the addition of the "Next Generation Sequencing (Genome/Exome sequencing/DNA sequencing) Global market - Forecast to 2020" report to their offering. Next generation sequencing market is one of the fastest growing segments in the genomics market with an estimated CAGR of around 17.0% in the next five years. The major factors such as rapid adoption of this technology by researchers and its usability as a substitute of microarray technology in addition to its higher throughput, increased accuracy, and affordable costs are driving the next generation sequencing market growth. However, factors such as reducing capital expenditure from academic institutions and huge dependability on grants funding from the government are hampering the next generation sequencing market growth. In addition, the analysis of large amount of data generated by sequencers, and data storage and management is posing a major challenge. The growth opportunities of this market include cloud computing, rising demand for pre-sequencing, developments in NGS fully integrated instruments and rising nanopore sequencing technology. There is a huge opportunity for this technology in the field of drug discovery, personalized medicine, agricultural and animal research. The North American region accounts for the largest share of the next generation sequencing market. The European and Asian markets are also expected to grow due to the favorable funding from the government to adopt this technology. The major factors contributing to this market growth include rising adoption by new customers, rising adoption of high-throughput sequencing platforms by government organizations such as Biotechnology and Biological Sciences Research Council (BBSRC) (U.K.) and NHGRI (National Human Genome Research Institute) (U.S.). Key Topics Covered: 1 Executive Summary 2 Introduction 3 Market Analysis 4 Next Generation Sequencing Market, By Products 5 Next Generation Sequencing Market Value And Volume Analysis, By Technology 6 Next Generation Sequencing Market, By End Users/Laboratories 7 Next Generation Sequencing Market Value And Volume Analysis, By Application Area 8 Geographic Analysis 9 Company Developments 10 Major Player Profiles - Agilent Technologies, Inc. - Beijing Genome Institute - Biomatters, Ltd. - Genomatix Software Gmbh - Illumina Inc. - Life Technologies Corp. - Pacific Biosciences of California Inc. - QIAGEN N.V - Roche Holding Ltd. - Strand Life Sciences Pvt. Ltd. For more information visit http://www.researchandmarkets.com/research/h5...generation
PACB: 6.72 (-0.25), A: 40.98 (+0.18), ILMN: 190.17 (+0.32)

Agilent Technologies Post Earnings: Don't Expect Many Surprises Going Forward
Hunter Straus - at Seeking Alpha - Mon Nov 17, 8:46PM CST

A: 40.98 (+0.18)

AGILENT TECHNOLOGIES
at Investor's Business Daily - Mon Nov 17, 5:50PM CST
AGILENT TECHNOLOGIES (A), an instrument maker, said Q4 EPS rose 8.6% to 88 cents, missing by a penny. Revenue grew 5.1% to $1.805 bil, slightly missing views for $1.812 bil. Shares rose 0.2% to 41.30.
A: 40.98 (+0.18)

Agilent Technologies (A) Q1 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Mon Nov 17, 4:25PM CST

A: 40.98 (+0.18)

Agilent guides in-line, promises to return $500M
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 3:47PM CST

A: 40.98 (+0.18), KEYS: 30.83 (-0.17)

Agilent beats 4Q profit forecasts
Automated Insights - Mon Nov 17, 3:18PM CST
SANTA CLARA, Calif. (AP) _ Agilent Technologies Inc. (A) on Monday reported profit of $16 million in its fiscal fourth quarter.
A: 40.98 (+0.18)

Agilent misses by $0.01, revenue in-line
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 3:08PM CST

A: 40.98 (+0.18)

Agilent Technologies Reports Fourth-Quarter 2014 Results
Business Wire - Mon Nov 17, 3:05PM CST
--GAAP net income of $16 million, or $0.05 per share
A: 40.98 (+0.18)

Agilent Technologies (A) Stock Research Links

A Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cognito Unveils Phase 3 Results for Alzheimer Treatment

Updated Category News Views 292

Charting New Waters in Alzheimer's Treatment Well, here's one for the books, folks. Cognito Therapeutics just tossed their latest Phase 3 results from their so-called HOPE study into the ring. We're talking about Spectris AD, a non-drug, at-home gizmo that aims to be the next big thing for Alzheimer's. Yeah, the study didn't exactly hit a home run with the primary...

Continue Reading
PawnMate Boosts Inventory Efficiency for Pawnshops

Updated Category News Views 85

RFID Technology: Breathing New Life into Pawnshops Let's get things rolling with the cold, hard truth that pawnshops aren't exactly what most folks expect when it comes to cutting-edge technology. But times are a-changin', and PawnMate’s RFID Inventory Module is the latest twist in this industry storyline. It's like swapping out a rusty toolbox for a brand-new set of...

Continue Reading
LinkedIn Shines: Brands Face Social Media Slump

Updated Category News Views 77

LinkedIn: The Unsung Hero in Social Platforms In a world where social media seems to be as unpredictable as the stock market, LinkedIn is surprisingly holding the line. According to Vista Social's 2027 report, LinkedIn proudly boasts the highest median engagement rate among brand pages at 5.8%. Now, in the wild west of social media, where reach is getting tougher to snag,...

Continue Reading
Life Insurance: Evolving with Your Financial Journey

Updated Category News Views 56

Why Life Insurance Isn't Just a 'Set It and Forget It' Life insurance isn't some one-time deal you lock in and toss aside. Mike Newell, an insurance pro, highlights how life's shifts—whether in income, dependents, or debt—should drive tweaks to your coverage. As your life story unfolds, so too should the backbone of your financial security. Early Adulthood: Setting...

Continue Reading
Go NYC's Perks: Making Commutes Rewarding in NYC

Updated Category News Views 136

Go NYC's Perks: Turning Commutes into Gains I’ve seen a lot of schemes aimed at getting folks to change their travel habits, but this one from Go NYC caught my attention. These guys are trying to squeeze some extra value out of the daily grind for anyone hoofing it across the Big Apple. A new rewards program named Perks kicks off, offering all kinds of discounts and...

Continue Reading
Better Life Science: Revolutionizing At-Home STI Testing

Updated Category News Views 171

Paving a New Path for STI Testing Accessibility The landscape of STI testing is undergoing a significant shift, and Better Life Science is at the helm with their innovative STD Hero at-home testing service. With a splash in the latest AVN report, they're turning heads in both the clinical world and in mainstream society. This ain't just about checking boxes in health...

Continue Reading
PEGATRON Unveils AI and HPC Advances at SC26

Updated Category News Views 96

Revamping AI with High-Density Computing You know, back in the day, AI was just about training models and running basic inference. But now, it's all about these crazy agentic AI tasks—autonomous agents doing things I couldn't have imagined. PEGATRON's Evolution in Infrastructure PEGATRON's latest move at SC26 is a real leap forward in this ongoing AI saga. They're...

Continue Reading
Cheyenne Real Estate: Neighborhood Nuances and Choices

Updated Category News Views 156

Unearthing the Hidden Dynamics of Cheyenne's Real Estate You've got this picturesque vision in your head of Cheyenne, Wyoming—a sprawling cowboy town with its wild winds and wide-open spaces. But if you think all those neighborhoods are cut from the same cloth, you've got another thing coming. The real estate scene here is just as varied as the prairies stretching out...

Continue Reading
SGRY Acquisition Under Scrutiny: Fairness Questioned

Updated Category News Views 203

Questions Hover Over SGRY Acquisition Here's a real jaw-dropper for you. Surgery Partners, Inc. (NASDAQ: SGRY) is getting clocks cleaned in a fairness probe over its acquisition terms. If you thought this ride was smooth, think again—Levi & Korsinsky, LLP has put the brakes on any such assumptions, launching an investigation that’s sure to raise some eyebrows. What's...

Continue Reading
NVIDIA Faces Turbulent Storm with CEO Resignation

Updated Category News Views 139

Huang's Unexpected Exit and NVIDIA's Rocky Road Well, talk about drama in Silicon Valley. When executives start stumbling, it's not just some PR nightmare—it's a full-on crisis. NVIDIA's co-founder and CEO Jensen Huang is calling it quits, and not on some smooth, idyllic note. No, this is the kind of exit that investors dread. You’ve got affairs, security concerns,...

Continue Reading

Top 5 Most Recently Viewed Articles

Nord Anglia's Private Schools Shine in 2026 National Rankings

Updated Category News Views 363

Nord Anglia's Schools Excel in National Rankings Nord Anglia schools ranked in the top 0.5 to 2% nationally Nord Anglia Education is proud to announce that its schools across the United States have achieved remarkable positions among the leading private schools nationwide, according to the latest Niche rankings for 2026. Unveiling Exceptional Educational Achievements This...

Continue Reading
Ingevity's Leadership Change: New Interim CEO Appointed

Updated Category News Views 151

Ingevity Announces CEO Transition Ingevity Corporation (NYSE: NGVT) has experienced a significant change in its leadership with John Fortson stepping down as president and chief executive officer. Following his departure, the company has entrusted board director Luis Fernandez-Moreno with the role of interim president and CEO while a search is underway for a permanent...

Continue Reading
Projected Growth of Supply Chain Security Market by 2030

Updated Category News Views 165

Growth Prospects of the Supply Chain Security Market The global Supply Chain Security Market is set for significant growth, projected to reach USD 5.14 billion by 2030, up from USD 2.52 billion in 2024. The expected compound annual growth rate (CAGR) during this period is 12.6%, indicating robust expansion in a field that safeguards vital supply chain operations. Scope...

Continue Reading
KLA Corporation's Impressive Fiscal 2026 Q2 Performance Review

Updated Category News Views 249

KLA Corporation's Fiscal 2026 Quarter Two Results Overview KLA Corporation (NASDAQ: KLAC) has reported robust financial results for the second quarter of fiscal year 2026, significantly surpassing expectations. These results underline the company’s powerful position within the semiconductor manufacturing industry. Financial Highlights Revenue Performance The company's...

Continue Reading
Heidi Hunter Steps Up as Vice Chair at Bavarian Nordic Board

Updated Category News Views 152

Heidi Hunter's New Role at Bavarian Nordic Recently, Bavarian Nordic A/S (Copenhagen: BAVA) announced an exciting development by appointing Heidi Hunter as the new Vice Chair of its Board of Directors. This decision follows the recent elevation of Anne Louise Eberhard to Chair, marking a shift in leadership aimed at steering the company forward in the pharmaceutical...

Continue Reading